RxDoctor Payments DataLook up a doctor →

Luis Omphroy, MD

Ophthalmology · Aiea, HINPI 1528121423

Payments from drug & device makers

$24,520in general payments, 2019–2025

Across 562 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$4K
  • Amgen$3K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • plus $9K from 33 others

What the payments were for

  • Consulting fees$2,1329%
  • Food & beverage$21,42587%
  • Education$800%
  • Gifts$450%
  • Other$8383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,520 in reported general payments places this provider in the 85th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$284,522
Medicare patients
668
Services billed
2,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod103$45,685
RestasisCyclosporine20$20,651
TyrvayaVarenicline Tartrate14$9,045
CombiganBrimonidine Tartrate/Timolol26$9,002
Prednisolone Acetate145$7,514
TobradexTobramycin/Dexamethasone28$7,408
RhopressaNetarsudil Mesylate14$5,692
MoxifloxacinMoxifloxacin Hcl185$5,234
Tobramycin-DexamethasoneTobramycin/Dexamethasone85$5,199
SimbrinzaBrinzolamide/Brimonidine Tart15$3,977
Dorzolamide-TimololDorzolamide/Timolol/Pf23$3,679
Tobradex StTobramycin/Dexamethasone15$3,457
Bepotastine Besilate20$3,217
Latanoprost142$3,143
Timolol Maleate32$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$1,187$45,685103 claims
AbbVieRestasis, Combigan$1,115$29,65346 claims
Oyster Point Pharma, Inc.Tyrvaya$410$9,04514 claims
Aerie Pharmaceuticals, Inc.Rhopressa$492$5,69214 claims
AlconSimbrinza$4,269$3,97715 claims
Eyevance Pharmaceuticals LLCTobradex St$36$3,45715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →